Dean Capital Investments Management LLC purchased a new stake in shares of Envista Holdings Corporation (NASDAQ:NVST) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 21,467 shares of the company’s stock, valued at approximately $598,000.
Other institutional investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new stake in shares of Envista in the third quarter worth about $46,000. SG Americas Securities LLC purchased a new stake in shares of Envista in the third quarter worth about $173,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Envista in the third quarter worth about $218,000. Eos Focused Equity Management L.P. purchased a new stake in shares of Envista in the third quarter worth about $1,723,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of Envista in the third quarter worth about $55,215,000.
In other news, CEO Amir Aghdaei bought 10,000 shares of Envista stock in a transaction on Friday, September 20th. The stock was acquired at an average price of $22.00 per share, with a total value of $220,000.00. Also, CFO Howard H. Yu bought 2,000 shares of Envista stock in a transaction on Friday, September 20th. The shares were purchased at an average cost of $22.00 per share, with a total value of $44,000.00. Insiders have acquired 13,000 shares of company stock valued at $286,000 in the last three months.
NASDAQ NVST traded down $0.05 during trading hours on Tuesday, reaching $28.25. The company’s stock had a trading volume of 1,516 shares, compared to its average volume of 888,982. Envista Holdings Corporation has a 1-year low of $25.65 and a 1-year high of $30.80. The firm has a 50-day moving average price of $28.37.
Envista (NASDAQ:NVST) last announced its earnings results on Thursday, October 24th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. The firm had revenue of $659.30 million for the quarter, compared to analyst estimates of $669.45 million. Envista’s quarterly revenue was down 3.0% compared to the same quarter last year.
Envista Holdings Corporation manufactures and sells dental products in the United States and internationally. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Ormco, Insignia, AOA, and Spark brands.
Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers
Want to see what other hedge funds are holding NVST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Envista Holdings Corporation (NASDAQ:NVST).
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.